Table 3.
Summary statistics for apixaban and atenolol pharmacokinetic parameters
| Parameter | Apixaban
|
Atenolol
|
||||||
|---|---|---|---|---|---|---|---|---|
| Treatment A (n=15) |
Treatment C (n=14) |
Ratio of adjusted geometric meansa
|
Treatment B (n=14) |
Treatment C (n=15) |
Ratio of adjusted geometric meansa
|
|||
| Point estimate, C vs A | 90% CI | Point estimate, C vs B | 90% CI | |||||
| Cmax (ng/mL) | 216 (33) | 180 (32) | 0.82 | 0.75, 0.89 | 603 (39) | 598 (33) | 0.98 | 0.84, 1.13 |
| AUC0–t (ng·h/mL) | 2103 (31) | 1838 (33) | 0.85 | 0.79, 0.92 | 5500 (29) | 5528 (22) | 1.00 | 0.90, 1.11 |
| AUCinf (ng·h/mL) | 2157 (31) | 1878 (33) | 0.85 | 0.78, 0.92 | 5596 (29) | 5649 (22) | 1.00 | 0.91, 1.11 |
| t1/2 (h), mean (SD) | 13.9 (6.1) | 11.7 (3.8) | – | – | 8.33 (1.64) | 8.57 (1.89) | – | – |
| Tmax (h), median (min, max) | 3 (1, 4) | 4 (2, 4) | – | – | 3 (1, 6) | 2 (2, 4) | – | – |
Notes:
The ratio of geometric means is estimated from the linear mixed-effect model, with treatment as fixed effect and subject as repeated measure. Geometric mean (CV %), unless otherwise noted. A, apixaban 10 mg. B, atenolol 100 mg. C, apixaban 10 mg + atenolol 100 mg.
Abbreviations: AUC0–t, area under the plasma concentration curve from time 0 to time of the last quantifiable concentration following a single dose; AUCinf, area under the plasma concentration curve from time 0 extrapolated to time infinity; CI, confidence interval; Cmax, maximum observed plasma concentration; CV, coefficient of variation; min, minimum; max, maximum; SD, standard deviation; t1/2, plasma half-life; Tmax, time of the maximum observed plasma concentration.